Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Home
Zydus Lifesciences Limited
Press Release Dec 13 2021
Dec 13 2021
4 min read

Press Release Dec 13 2021

Cadila Healthcare Limited has informed the Exchange regarding a press release dated December 13, 2021, titled "Zydus to begin Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Cryopyrin-Associated Periodic Syndrome (CAPS) in Australia".

View Attachment